UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Bayesian Precision Medicine

Thall, Peter F.

1, 2024

Volltextzugriff (PDF)

A phase I‐II design based on periodic and continuous monitoring of disease status and the times to toxicity and death

Statistics in medicine, 2020-07, Vol.39 (15), p.2035-2050

2020

Volltextzugriff (PDF)

Precision Bayesian phase I‐II dose‐finding based on utilities tailored to prognostic subgroups

Statistics in medicine, 2021-10, Vol.40 (24), p.5199-5217

2021

Volltextzugriff (PDF)

Bayesian treatment screening and selection using subgroup-specific utilities of response and toxicity

Biometrics, 2023-09, Vol.79 (3), p.2458-2473

2023

Volltextzugriff (PDF)

A generalized phase 1-2-3 design integrating dose optimization with confirmatory treatment comparison

Biometrics, 2024-01, Vol.80 (1)

2024

Volltextzugriff (PDF)

Making Patient-Specific Treatment Decisions Using Prognostic Variables and Utilities of Clinical Outcomes

Cancers, 2021-06, Vol.13 (11), p.2741

2021

Volltextzugriff (PDF)

An adaptive trial design to optimize dose‐schedule regimes with delayed outcomes

Biometrics, 2020-03, Vol.76 (1), p.304-315

2020

Volltextzugriff (PDF)

BAGS: A Bayesian Adaptive Group Sequential Trial Design With Subgroup-Specific Survival Comparisons

Journal of the American Statistical Association, 2021-03, Vol.116 (533), p.322-334

2021

Volltextzugriff (PDF)

Use of CAR-Transduced Natural Killer Cells in CD19-Positive Lymphoid Tumors

The New England journal of medicine, 2020-02, Vol.382 (6), p.545-553

2020

Volltextzugriff (PDF)

Adaptive Enrichment Designs in Clinical Trials

Annual review of statistics and its application, 2021-03, Vol.8 (1), p.393-411

Thall, Peter F.

2021

Volltextzugriff (PDF)

ROMI: a randomized two-stage basket trial design to optimize doses for multiple indications

Biometrics, 2024-10, Vol.80 (4)

2024

Volltextzugriff (PDF)

Interpreting Randomized Controlled Trials

Cancers, 2023-09, Vol.15 (19), p.4674

2023

Volltextzugriff (PDF)

Bayesian cancer clinical trial designs with subgroup-specific decisions

Contemporary clinical trials, 2020-03, Vol.90, p.105860-105860, Article 105860

Thall, Peter F.

2020

Volltextzugriff (PDF)

A generalized outcome-adaptive sequential multiple assignment randomized trial design

Biometrics, 2024-07, Vol.80 (3)

2024

Volltextzugriff (PDF)

Bayesian Nonparametric Estimation for Dynamic Treatment Regimes With Sequential Transition Times

Journal of the American Statistical Association, 2016-09, Vol.111 (515), p.921-950

2016

Volltextzugriff (PDF)

Multi-institutional study of post-transplantation cyclophosphamide as single-agent graft-versus-host disease prophylaxis after allogeneic bone marrow transplantation using myeloablative busulfan and fludarabine conditioning

Journal of clinical oncology, 2014-11, Vol.32 (31), p.3497-3505

2014

Volltextzugriff (PDF)

Bayesian group sequential enrichment designs based on adaptive regression of response and survival time on baseline biomarkers

Biometrics, 2022-03, Vol.78 (1), p.60-71

2022

Volltextzugriff (PDF)

Using Data Augmentation to Facilitate Conduct of Phase I–II Clinical Trials With Delayed Outcomes

Journal of the American Statistical Association, 2014-06, Vol.109 (506), p.525-536

2014

Volltextzugriff (PDF)

Determining the Effective Sample Size of a Parametric Prior

Biometrics, 2008-06, Vol.64 (2), p.595-602

2008

Volltextzugriff (PDF)

Generalized phase I‐II designs to increase long term therapeutic success rate

Pharmaceutical statistics : the journal of the pharmaceutical industry, 2023-07, Vol.22 (4), p.692-706

2023

Volltextzugriff (PDF)

Bayesian Dose-Finding in Two Treatment Cycles Based on the Joint Utility of Efficacy and Toxicity

Journal of the American Statistical Association, 2015-06, Vol.110 (510), p.711-722

2015

Volltextzugriff (PDF)

Platinum-Based Chemotherapy for Variant Castrate-Resistant Prostate Cancer

Clinical cancer research, 2013-07, Vol.19 (13), p.3621-3630

2013

Volltextzugriff (PDF)

Propensity Score-based Comparison of Long-term Outcomes With 3-Dimensional Conformal Radiotherapy vs Intensity-Modulated Radiotherapy for Esophageal Cancer

International journal of radiation oncology, biology, physics, 2012-12, Vol.84 (5), p.1078-1085

2012

Volltextzugriff (PDF)

Neoadjuvant Paclitaxel, Ifosfamide, and Cisplatin Chemotherapy for Metastatic Penile Cancer: A Phase II Study

Journal of clinical oncology, 2010-08, Vol.28 (24), p.3851-3857

2010

Volltextzugriff (PDF)

1 – 25 von 497

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(402)
Mit Volltextzugriff
(456)

Publikationsform

2 weitere anzeigen...

Weniger anzeigen...

Sprache

Englisch
(497)

Erscheinungsjahr

n.n

Thema

Science & Technology
(249)
Life Sciences & Biomedicine
(208)
Humans
(202)
Mathematics
(120)
Physical Sciences
(116)
Statistics & Probability
(116)
Clinical Trials
(89)
Male
(89)
Oncology
(87)
Middle Aged
(82)
Female
(78)
Medical Sciences
(73)
Aged
(70)
Biological And Medical Sciences
(69)
Adult
(66)
Bayes Theorem
(64)
Mathematical & Computational Biology
(57)
Treatment Outcome
(55)
Bayesian Analysis
(50)
Research Design
(45)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)
... seit 90 Tagen
(5)

Menü

Weitere Dienste

Einstellungen

Bayesian Precision Medicine

A phase I‐II design based on periodic and continuous monitoring of disease status and the times to toxicity and death

Precision Bayesian phase I‐II dose‐finding based on utilities tailored to prognostic subgroups

Bayesian treatment screening and selection using subgroup-specific utilities of response and toxicity

A generalized phase 1-2-3 design integrating dose optimization with confirmatory treatment comparison

Making Patient-Specific Treatment Decisions Using Prognostic Variables and Utilities of Clinical Outcomes

An adaptive trial design to optimize dose‐schedule regimes with delayed outcomes

BAGS: A Bayesian Adaptive Group Sequential Trial Design With Subgroup-Specific Survival Comparisons

Use of CAR-Transduced Natural Killer Cells in CD19-Positive Lymphoid Tumors

Adaptive Enrichment Designs in Clinical Trials

ROMI: a randomized two-stage basket trial design to optimize doses for multiple indications

Interpreting Randomized Controlled Trials

Bayesian cancer clinical trial designs with subgroup-specific decisions

A generalized outcome-adaptive sequential multiple assignment randomized trial design

Bayesian Nonparametric Estimation for Dynamic Treatment Regimes With Sequential Transition Times

Multi-institutional study of post-transplantation cyclophosphamide as single-agent graft-versus-host disease prophylaxis after allogeneic bone marrow transplantation using myeloablative busulfan and fludarabine conditioning

Bayesian group sequential enrichment designs based on adaptive regression of response and survival time on baseline biomarkers

Using Data Augmentation to Facilitate Conduct of Phase I–II Clinical Trials With Delayed Outcomes

Determining the Effective Sample Size of a Parametric Prior

Generalized phase I‐II designs to increase long term therapeutic success rate

Bayesian Dose-Finding in Two Treatment Cycles Based on the Joint Utility of Efficacy and Toxicity

Platinum-Based Chemotherapy for Variant Castrate-Resistant Prostate Cancer

Propensity Score-based Comparison of Long-term Outcomes With 3-Dimensional Conformal Radiotherapy vs Intensity-Modulated Radiotherapy for Esophageal Cancer

Neoadjuvant Paclitaxel, Ifosfamide, and Cisplatin Chemotherapy for Metastatic Penile Cancer: A Phase II Study

Safety, efficacy and determinants of response of allogeneic CD19-specific CAR-NK cells in CD19+ B cell tumors: a phase 1/2 trial

Suchergebnisse filtern